GCA-016 · formulation research and preclinical characterisation · Platform science

VAGINAL FORMULATIONS

Start with her biology—
not only the molecule.

We are investigating an Africa-led, lignin-based gel platform intended to support the vaginal milieu and enable future delivery of multiple active pharmaceutical compounds.

Iso-osmolar biomimetic formulation pipetting and epithelial barrier testing.

Programme:

Vaginal Formulations

Focus:

Platform science

Current stage:

Grant-funded research

Status:

GCA-016 · formulation research and preclinical characterisation

The problem

What goes inside a woman’s body should be designed to work with it.

A vaginal formulation is not only a vehicle for medicine. It enters a living environment. Our first question is whether the base respects the tissue, mucus, pH and protective bacteria—before asking what medicine it can carry.

Sawazisha Formulation Science
Our response

A respectful base for more than one future medicine.

We are investigating an Africa-led, lignin-based gel platform intended to support the vaginal milieu and enable future delivery of multiple active pharmaceutical compounds.

Built with purpose

For formulation scientists, preclinical researchers, manufacturers and clinical collaborators.

Potential impact

What progress could unlock.

These are the outcomes guiding development. Product claims will follow the evidence generated at the appropriate stage.

01

Advance locally led formulation capability

02

Design affordability, comfort and biological fit into the platform

03

Create an adaptable base for future vaginal products

Evidence behind this work

Emotion opens the door. Evidence keeps us honest.

These sources support the clinical category or scientific rationale. They do not establish product-specific safety, efficacy or regulatory approval for Vaginal Formulations.

Development pathway

Where Vaginal Formulations stands today.

Current stage: Grant-funded research

Formulation optimisation and preclinical characterisation